Most people who have had a cholesterol test have never seen their lipoprotein(a). It is not usually measured when cholesterol is checked, and it does not respond to the diet-and-exercise advice that dominates conversations about cholesterol. Yet for a sizeable minority of people, it is one of the most important numbers about their cardiovascular ageing — and it is written into their genes from birth.
This article explains what lipoprotein(a), usually shortened to Lp(a), actually is, why it independently raises the risk of heart attack, stroke and a specific heart-valve problem, why lifestyle barely shifts it, and how to make sense of your own result. It is educational, not medical advice — for any decision about your own health, see the medical disclaimer and speak to a clinician.
What lipoprotein(a) actually is
Lp(a) is a cholesterol-carrying particle that looks, at first glance, like ordinary LDL — the so-called "bad cholesterol". It has an LDL-like core wrapped around a single molecule of apolipoprotein B, the protein that marks a particle as artery-damaging. What sets Lp(a) apart is an extra protein bolted on top, called apolipoprotein(a), which is looped into a distinctive shape and coded by a gene, LPA, that varies enormously from person to person (Tsimikas, 2017).
That structure matters. Because Lp(a) carries an ApoB molecule, it behaves as an atherogenic — artery-clogging — particle in its own right. But it appears to be more dangerous than the LDL it resembles. A large genetic analysis that compared particles on a like-for-like basis concluded that, particle for particle, Lp(a) is markedly more atherogenic than ordinary LDL (Björnson et al., 2024). In other words, it may take fewer Lp(a) particles to do comparable damage — which is why even a moderate concentration can carry meaningful risk.
Why it matters for your arteries — and your heart valves
The evidence that Lp(a) is not just an innocent bystander is unusually strong, because it comes from three independent directions that point the same way.
First, large-scale observational data. A meta-analysis pooling 126,634 people across 36 prospective studies found a continuous, independent association between Lp(a) concentration and the risk of coronary heart disease and stroke — the higher the level, the higher the risk, and the relationship held even after accounting for other cholesterol measures (Erqou et al., 2009).
Second, genetics. Because your Lp(a) level is set largely by the LPA gene you inherit, researchers can use those inherited differences as a natural experiment — a design that helps separate cause from coincidence. Studies in the Copenhagen population found that people genetically programmed for high Lp(a) had a markedly higher rate of heart attack, consistent with Lp(a) being a cause rather than merely a marker (Kamstrup et al., 2009). A separate genetic study identified variants in the LPA region as among the strongest inherited signals for coronary disease, acting through their effect on Lp(a) concentration — again pointing to a causal role (Clarke et al., 2009).
Third, a distinctive additional risk beyond the arteries: the aortic valve. Analysing 77,680 people, researchers found that high Lp(a) was associated with a substantially increased risk of calcific aortic valve stenosis, a stiffening of the valve that becomes more common with age (Kamstrup et al., 2014). It points to Lp(a) as a contributor to a valve condition whose risk factors are still being mapped.
Taken together, major scientific bodies now describe Lp(a) as a genetically determined, causal and common risk factor for atherosclerotic cardiovascular disease (Reyes-Soffer et al., 2022; Kronenberg et al., 2022).
The part you can't change: it is inherited
Here is the fact that reframes everything about Lp(a): unlike LDL, your level is roughly 80–90% determined by genetics and is essentially set for life (Kronenberg et al., 2022). It does not drift much with a good week or a bad one, and unlike some lipid measures it does not require fasting before the test (Kronenberg et al., 2022). For most people it stays remarkably stable across the years, which is why a single measurement is generally considered representative for life (Kronenberg et al., 2022).
It is also common. Consensus statements from the European Atherosclerosis Society and the American Heart Association estimate that around one in five people carry an Lp(a) level high enough to matter (Reyes-Soffer et al., 2022; Kronenberg et al., 2022). Many of them will have a completely normal standard cholesterol panel, which is one reason a raised Lp(a) can go unnoticed. It may help explain a family history of early heart disease that a conventional lipid profile leaves unexplained.
Because the number is so stable and so genetic, guidelines increasingly suggest that a single measurement at some point in adult life is enough for most people — you rarely need to repeat it (Kronenberg et al., 2022).
Why the usual advice barely moves it
This is where Lp(a) frustrates the standard playbook. The dietary changes, exercise and weight loss that can meaningfully lower LDL have little effect on Lp(a). Even statins — the mainstay of LDL treatment — do not lower it; reviews note that statins tend to leave Lp(a) unchanged or even nudge it slightly higher (Tsimikas, 2017).
That has a practical consequence. In an analysis of individual patient data from statin trials, Lp(a) still predicted cardiovascular events in people who were already on statin therapy and whose LDL had been brought down (Willeit et al., 2018). In other words, treating LDL well does not erase the risk that Lp(a) carries — the two are partly separate problems.
None of this means a raised Lp(a) is a dead end. It changes what the number is for. Rather than something to be dieted away, a high Lp(a) is better understood as context — a reason a clinician might look harder at every other risk factor that can be improved, from LDL and blood pressure to smoking and blood sugar, because lowering the overall burden matters more when one fixed factor is already stacked against you.
What is on the horizon
For years, the absence of a treatment that specifically targeted Lp(a) made measuring it feel academic. That is changing. A newer class of drugs is designed to switch off production of the apolipoprotein(a) protein at its source. In early-phase trials, an antisense therapy lowered Lp(a) dramatically (Tsimikas et al., 2020), and a small-interfering-RNA therapy did so as well (O'Donoghue et al., 2022).
It is important to be precise about what these results do and do not show. These were studies of how much the drugs lower the number — not yet proof that lowering Lp(a) prevents heart attacks or strokes. Those cardiovascular-outcome trials are ongoing, the therapies are investigational and not approved for this use, and whether reducing Lp(a) translates into fewer events is a question the science has not yet answered. What has shifted is that the question is now being seriously tested — which is one reason knowing your level has become more useful than it once was.
How to read your Lp(a) result
A few things help make sense of the number. Lp(a) is reported in two different units — nmol/L (a count of particles, now the preferred measure) or mg/dL (a measure of mass) — and the two do not convert cleanly, so it is worth checking which one your lab used (Kronenberg et al., 2022). As a rough guide, consensus statements commonly describe levels above about 125 nmol/L (roughly 50 mg/dL) as the point where risk starts to climb, with higher levels carrying more (Reyes-Soffer et al., 2022).
In practice, Lp(a) is most often measured from a venous blood sample taken at a clinic or lab, rather than a home finger-prick. And because the result is so stable, a single reading usually tells you what you need to know — there is little value in repeating it unless a clinician advises otherwise.
A high result is a prompt for a conversation, not a verdict. It is one piece of a wider picture that includes your ApoB, the rest of your lipid panel, blood pressure and family history — and your GP or a lipid specialist is best placed to put it all together.
Why this belongs in a longevity check
Lp(a) is one of the most under-recognised contributors to atherosclerotic cardiovascular disease — a common, causal, lifelong risk factor that a standard cholesterol test usually skips entirely (Reyes-Soffer et al., 2022; Kronenberg et al., 2022). Measuring it once gives you information you would otherwise never see, and information that stays true for the rest of your life.
Omniwo measures Lp(a) as part of the Premium Wellness Check, a venous panel that also covers ApoB, the full lipid profile and dozens of other markers — or you can read more about the marker itself on our lipoprotein(a) page. Knowing the number is the first step; what it means for you is a conversation for you and a clinician.
Omniwo's tests and content are for wellness and educational insight. They are not a medical device, do not diagnose, treat, cure or prevent any disease, and do not replace advice from a qualified healthcare professional.
This article is educational and not medical advice. See our medical disclaimer.
Sources
- Erqou S, Kaptoge S, Perry PL, et al. (Emerging Risk Factors Collaboration). Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412–423. doi:10.1001/jama.2009.1063 (PMID: 19622820)
- Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331–2339. doi:10.1001/jama.2009.801 (PMID: 19509380)
- Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. New England Journal of Medicine. 2009;361(26):2518–2528. doi:10.1056/NEJMoa0902604 (PMID: 20032323)
- Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. Journal of the American College of Cardiology. 2014;63(5):470–477. doi:10.1016/j.jacc.2013.09.038 (PMID: 24161338)
- Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. Journal of the American College of Cardiology. 2017;69(6):692–711. doi:10.1016/j.jacc.2016.11.042 (PMID: 28183512)
- Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022;42(1):e48–e60. doi:10.1161/ATV.0000000000000147 (PMID: 34647487)
- Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. 2022;43(39):3925–3946. doi:10.1093/eurheartj/ehac361 (PMID: 36036785)
- Willeit P, Ridker PM, Nestel PJ, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018;392(10155):1311–1320. doi:10.1016/S0140-6736(18)31652-0 (PMID: 30293769)
- Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. New England Journal of Medicine. 2020;382(3):244–255. doi:10.1056/NEJMoa1905239 (PMID: 31893580)
- O'Donoghue ML, Rosenson RS, Gencer B, et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. New England Journal of Medicine. 2022;387(20):1855–1864. doi:10.1056/NEJMoa2211023 (PMID: 36342163)
- Björnson E, Adiels M, Taskinen MR, et al. Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis. Journal of the American College of Cardiology. 2024;83(3):385–395. doi:10.1016/j.jacc.2023.10.039 (PMID: 38233012)